#' Women's Interagency HIV Study
#'
#' A dataset containing competing risks information for women with HIV;
#' recording the time to treatment, or the time to developing AIDS or death. The
#' time may also be censored.
#'
#' @format A data frame with 1164 rows and 6 variables: \describe{
#'   \item{time}{time to the event} \item{status}{denotes which event occurred.
#'   0 denotes censoring, 1 denotes HIV treatment began, and 2 denotes AIDS
#'   developed or the patient died} \item{ageatfda}{patient age at time first
#'   treatment approved} \item{idu}{binary specifying if the patient has a
#'   history of drug injections (1 if true)} \item{black}{binary specifying if
#'   the patient is black (1 if true)} \item{cd4nadir}{blood count of CD4 cells}
#'   }
#' @source The data was obtained from the randomForestSRC R package.
#'
#' @references Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, Gange
#'   S, Barranday Y, Holman S, Weber K, Young MA (2005). “The Women’s
#'   Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to
#'   the Bench.” Clinical and Vaccine Immunology, 12(9), 1013–1019.
#'   doi:10.1128/CDLI.12.9.1013-1019.2005.
#'   
"wihs"